Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Sialorrhea

Sialorrhea

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Sialorrhea

6 trials tracked for Sialorrhea: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 241 citations.

6Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 1 Other / NA 2
  1. Phase 3 Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects Completed · 241 cited
  2. Phase 3 Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults Completed · 1 cited
  3. Phase 3 Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Completed
  4. Phase 2 Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism Completed
  5. N/A Oral Health Literacy Tailored Communication Completed
  6. N/A Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Sialorrhea: what the trials found

MYOBLOC injection demonstrated a statistically significant reduction in Unstimulated Salivary Flow Rate (USFR) at week 4 post-injection 1. This intervention also resulted in a statistically significant improvement in Clinical Global Impression Change (CGI-C) scores by the same timeframe 1.

Clinical data for MYOBLOC indicates consistent reductions in USFR across multiple treatment sessions 2. Furthermore, patients receiving MYOBLOC showed statistically significant improvements in Clinical Global Impression of Severity (CGI-S) scores 2.

Recent results — preliminary, needs further review

  • Incobotulinum Toxin A was associated with a reduction in salivary weight and improved Drooling Frequency and Severity Scale (DFSS) scores, though these findings are not yet corroborated 4.
  • Atropine (0.01mg/kg) showed no significant difference in Salivary Flow Rate between study groups 6.
  • Tailored oral health literacy instruction was evaluated but lacks reported outcome data for inclusion in established evidence 5.

For the clinician treating this condition

  • MYOBLOC is associated with a statistically significant reduction in Unstimulated Salivary Flow Rate (USFR) and improved clinical global impression scores [1, 2].
  • Clinical assessments indicate that MYOBLOC provides consistent reductions in salivary flow across multiple treatment sessions 2.

AI synthesis of 5 cited trials, updated Jul 18, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Botulinum toxin type A effectively manages sialorrhea in pediatric and adult neurological disorders
Neurology Sys. Review
Botulinum toxin type A effectively manages sialorrhea in pediatric and adult neurological disorders Botulinum toxin helps manage drooling in neurological conditions
This narrative review examines the use of botulinum toxin type A for managing sialorrhea in patients with cerebral palsy and Parkinson's dis…
Newer insights show how botulinum toxin can help children and adults with neurological disorders manage excessive drooling.
Frontiers Jul 17, 2026